By Professor David Goldstein

Conference Posters

Reni M; Riess H; O'Reilly EM; Park JO; Hatoum H; Saez BL; Salminen T; Oettle H; Lopez R; Dowden SD; Karthaus M; Tabernero J; Van Cutsem E; Philip PA; Goldstein D; Berlin J; Tempero MA, 2020, 'Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region.', Vol. 38, pp. 4515 - 4515, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.4515

Iioanni L; maharaj A; loughan J; zalcberg J; earnest A; Goldstein D; Kench J; Merrett N; christophi C; croagh D; pilgrim C; burmeister E; white K; neale R; green S; evans S, 2019, 'Prognostic models to predict survival in patients with pancreatic cancer: A systematic review', Bangkok, presented at ASM RACS, Bangkok, 06 May 2019 - 10 May 2019

Wang X; crowe PC; goldstein DG; Yang JY, 2017, 'In vitro and in vivo effect of targeting CDK4/6 and mTOR singly or together in sarcoma cell lines', Adelaide, Australia, presented at 2017 Annual Sarcoma Conference, Adelaide, Australia, 13 October 2017 - 14 October 2017

Wang X; Crowe PC; Goldstein DG; Yang JY, 2017, 'Anti-prolifeative effect of targeting CDK4/6 and mTOR alone or in combination in sarcoma cell lines', Florence, Italy, presented at EACR-AACR-SIC: The Challenges of optimising immuno and targeted therapies: from cancer biology to the clinic, Florence, Italy, 24 June 2017 - 27 June 2017

Wang X; Crowe PJ; Goldstein D; Yang JL, 2015, 'Overcoming resistance of targeted EGFR/panHER monotherapy by inhibition of STAT3 escape pathway in sarcoma', Lorne, Victoria, Australia, Vol. 7, pp. 21496 - 21509, presented at 27th Lorne Cancer Conference 2015, Lorne, Victoria, Australia, 12 February 2015 - 14 February 2015, http://dx.doi.org/10.18632/oncotarget.7452

Lim HJ; Wang X; Goldstein ; Crowe , 2015, 'Targeting the PI3K/PTEN/AKT/mTOR pathway in sarcoma cell lines', Lorne, Victoria, Australia, presented at 27th Lorne Cancer Conference 2015, Lorne, Victoria, Australia, 12 February 2015 - 14 February 2015

Wang X; Goldstein ; Crowe ; Yang , 2014, 'Effect and mechanism of PF299804 alone and in combination with STAT3 inhibitor in human sarcoma cell lines', San Diego, CA, PA, presented at The 105th Annual Meeting of the American Association for Cancer Research 2014, San Diego, CA, PA, 05 April 2014 - 09 April 2014, http://dx.doi.org/10.1158/1538-7445.AM2014-172

Wang X; Goldstein D; Crowe P; Yang J, 2013, 'Mechanisms of gefitinib alone and in combination therapy in soft tissue sarcoma cell lines', Boston, MA, US, presented at Molecular Targets and Cancer Therapeutics 2013, Boston, MA, US, 19 October 2013 - 23 October 2013

Wang X; Goldstein D; Crowe P; Yang J, 2013, 'STAT3 inhibitor S3I-201 suppresses human osteosarcoma cell growth', Lorne, Victoria, Australia, presented at 25th Lorne Cancer Conference 2013, Lorne, Victoria, Australia, 14 February 2013 - 16 February 2013

Wang X; Goldstein D; Crowe P; Yang J, 2012, 'Treatment of soft tissue sarcoma cells by EGFR and/or STAT3 inhibitors', presented at The 103rd Annual Meeting of AACR 2012, 31 March 2012 - 04 April 2012

Wang X; Goldstein D; Crowe P; Yang J, 2012, 'STAT3-targeted therapy on human soft tissue sarcomas', Lorne, Victoria, Australia, presented at 24th Lorne Cancer Conference 2012, Lorne, Victoria, Australia, 09 February 2012 - 11 February 2012

Back to profile page